2 Biotech Stocks That Could Soar This Year

CRISPR Therapeutics and Summit Therapeutics are positioned for potential stock-moving clinical and commercial catalysts in 2026: CRISPR is advancing early-stage candidates CTX310 (LDL/TG lowering), CTX320 (Lp(a) lowering) and SRSD107 (long‑acting anticoagulant) while expecting commercial traction from approved product Casgevy; Summit’s ivonescimab (licensed from Akeso) is in multiple Phase 3 trials including a squamous NSCLC study with data expected later this year and has shown superiority to Keytruda in Chinese studies. Both stories carry substantial upside if clinical readouts and regulatory progress succeed, but material risks remain from clinical setbacks, high costs/complex administration for gene editing, and payer acceptance that could limit commercial adoption.

Analysis

Market structure: Positive clinical outcomes would directly benefit SMMT (ivonescimab) and CRSP (Casgevy + early gene-editing assets), CROs/CMOs serving them, and small-cap biotech indices; incumbents in PD-1/PD-L1 (e.g., MRK/Keytruda) face localized share loss in NSCLC subsegments. One-time curative/long-acting therapies (CRSP) compress recurring demand and shift payer dynamics, raising pricing friction and increasing manufacturing scarcity (viral vectors/CMO capacity) that can sustain premium pricing for suppliers.

Risk assessment: Tail risks include FDA non-approval or requests for bridging U.S. data (high-impact, ~10-30% probability), class safety/regulatory clampdowns for gene editing (<5-10%), reimbursement refusals that cap revenue (>$1M per course unlikely to scale). Immediate (days-weeks): implied vol spikes around trial announcements; short-term (1–6 months): Phase-3 readouts and quarterly Casgevy sales; long-term (1–3 years): payer negotiations and manufacturing scale.

Trade implications: Event-driven longs with strict size control and option hedges are optimal: buy SMMT ahead of Phase 3 and use call spreads to cap premium; take a small, hedged starter position in CRSP to play commercialization upside while protecting downside with puts. Expect implied vol to rise 30–70% into readouts, favoring bought calls/call spreads or put protection over naked short premium. Rotate 1–2% portfolio weight from large-cap IO staples into event biotech exposure.

Contrarian angles: The market underprices payer/manufacturing risk for CRSP and overweights China-only efficacy for SMMT; success in Chinese trials has historically translated variably in the U.S. (past PD‑1 entrants show both wins and regulatory friction). If SMMT’s U.S. Phase 3 replicates China results (e.g., HR ≤0.80, p<0.05), upside is binary and large; if not, drawdowns of 40–70% are plausible as the narrative reverses quickly.

Key Decisions for Investors

• Establish a 2% portfolio long in SMMT (SMMT) shares ahead of the Phase‑3 squamous NSCLC readout later this year; pair with a 3–6 month protective 30% OTM put sized to cover 50% of the long notional. If topline shows superiority (pre‑specified primary met, HR ≤0.80 and p<0.05), add to 4% within one week; if missed, cut to zero or hedge further.
• Buy a cost‑capped SMMT call spread (9–12 month tenor) sized to 0.5% of portfolio: buy a 50% OTM call and sell a 150% OTM call (percentages of current spot) to capture binary upside while limiting premium outlay. Close on positive readout or if implied vol doubles and raw premium exceeds planned budget.
• Initiate a 1% long in CRSP (CRSP) equity to play Casgevy commercial ramp; simultaneously buy a 12‑month 25% OTM put (cost threshold ≤1% portfolio) to limit downside. Increase to 3% only if Casgevy reaches >$100M annualized run‑rate within four quarters or if CTX310 Phase‑1/2 shows ≥30% mean LDL reduction in published data.
• Deploy a pair trade: long SMMT 2% vs short MRK 0.5% (Merck) as a beta hedge to express idiosyncratic upside. Close or reduce the short if MRK moves >5% intraday or if SMMT misses its primary endpoint; tighten stops at a 40% adverse move on the long leg.